E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
Alireza Eghtedar,Hagop M. Kantarjian,Elias Jabbour,Susan O'Brien,Elizabeth M. Burton,Guillermo Garcia-Manero,Srdan Verstovsek,Farhad Ravandi,Gautam Borthakur,Marina Konopleva,Alfonso Quintás-Cardama,Jorge E. Cortes +11 more
TL;DR: It is concluded that treatment failure after first-line therapy with 2G-TKIs is mostly associated with toxicity or patient preference, and these patients respond well to alternative TKIs.
Journal ArticleDOI
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: A chart review analysis
TL;DR: Based on the guidelines, the rates of treatment monitoring and switching upon failure were low, demonstrating the need for improvement in CML care in community settings in the US.
Journal Article
Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
TL;DR: The current treatment options for Ph+ ALL are summarized and the therapies that may become the standard of care in the near future are highlighted.
Journal ArticleDOI
Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome
Alfonso Quintás-Cardama,Hagop M. Kantarjian,Farhad Ravandi,Cielo Foudray,Naveen Pemmaraju,Tapan M. Kadia,Gautam Borthakur,Naval Daver,Stefan Faderl,Elias Jabbour,Jorge E. Cortes,Guillermo Garcia-Manero +11 more
TL;DR: A pilot phase II study to determine the efficacy and safety of the combination of pracinostat and 5-azacitidine in hematological malignancies in patients with intermediate-2 or high risk MDS demonstrated excellent PK properties and target inhibition and was generally well tolerated.
Journal ArticleDOI
A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia
Nitin Jain,Kristen E. Stevenson,Eric S. Winer,Jacqueline S. Garcia,Richard Stone,Elias Jabbour,Farhad Ravandi,Jeremy M. Stewart,Dean R Legg,Hagop M. Kantarjian,Donna Neuberg,Anthony Letai,Marina Konopleva,Daniel J. DeAngelo +13 more
TL;DR: This phase I trial was performed to determine if venetoclax can be safely added to a reduced intensity chemotherapy regimen for older adults with untreated ALL and in patients with R/R ALL, and the overall response rate (ORR) rate was 100% with 9/10 (90%) achieving CR and 1 pt PR.